Abstract: The invention relates to enhancing a human sexual activity. The inventive means for enhancing a human sexual activity is embodied in the form of a light water containing at least 99.739 molecular % or at least 99.760 molecular % or at least 99.774 molecular % of the lighter 1H216O molecules and up to 100% the other forms of water molecules. The inventive method for enhancing a human sexual activity consists in administrating to a treatable person an effective quantity of the light water containing at least 99.739 molecular % or at least 99.760 molecular % or at least 99.774 molecular % of the lighter 1H216O molecules and up to 100% the other forms of water molecules. In the preferred embodiment of the method, an effective quantity of the light water containing at least 99.739 molecular % or at least 99.760 molecular % or at least 99.774 molecular % of the lighter 1H216O molecules and up to 100% the other forms of water molecules is administrated orally or parenterally.

Abstract: The invention relates to the method for decreasing postprandial glucose excursion in a mammal in need thereof comprising a step of administering to said mammal an effective amount of water comprising from 99.76 to 99.99 molecular % of isotopologue 1H20 at 0 to 240 min from the start of ingestion of a meal. Preferably, the effective amount water comprising from 99.76 to 99.99 molecular % of isotopologue 1H2160 is administered orally. Preferably, the effective amount of the water comprising from about 99.76 to about 99.99 molecular % of isotopologue 1H2160 is 0.1 to 20 g/kg body weight of a mammal. Further, invention relates to the medical food for decreasing postprandial glucose excursion in a mammal in need thereof which comprises water comprising from about 99.76 to about 99.99 molecular % of isotopologue 1H2160. Further, invention relates to use of water comprising from about 99.76 to about 99.

Abstract: The invention relates to the method of treating metabolic syndrome in a mammal in need thereof comprising a step of administering to said mammal an effective amount of water comprising from 99.76 to 99.99 molecular % of isotopologue 1H216O. Further, invention relates to the medical food for treating metabolic syndrome in a mammal in need thereof which comprises water comprising from 99.76 to about 99.99 molecular % of isotopologue 1H216O. Further, invention relates to the use of water comprising from about 99.76 to about 99.99 molecular % of isotopologue 1H216O for the manufacture of a medical food for treating metabolic syndrome in a mammal in need thereof.

Abstract: The invention relates to method for suppressing appetite and food intake in a mammal in need thereof comprising a step of administering to said mammal an effective amount of water comprising from 99.76 to 99.99 molecular % of isotopologue 1H2160. Further, invention relates to medical food for suppressing appetite and food intake in a mammal in need thereof which comprises water comprising from about 99.76 to about 99.99 molecular % of isotopologue 1H2160. Further, invention relates to the use of water comprising from about 99.76 to about 99.99 molecular % of isotopologue 1H2160 for the manufacture of a medical food for suppressing appetite and food intake in a mammal in need thereof. Because of suppressing appetite and food intake, this invention is particularly useful for treating overweight and obesity in a mammal in need thereof. Preferably, the mammal is human.

Abstract: The invention relates to substance and method for treating neoplasms in mammals. A substance for treating neoplasm comprises water comprising from 99.76 to 99.99 molecular % of light isotopologue 1H216O and up to 100% of residual isotopologues. A method for treating neoplasm comprises a step of administering to a mammal in need thereof an effective amount of water comprising from about 99.76 to about 99.99 molecular % of light isotopologue 1H216O and up to 100% of residual isotopologues. Preferably, the effective amount of the water comprising from about 99.76 to about 99.99 molecular % of light isotopologue 1H216O and up to 100% of residual isotopologues is administered orally or parenterally. Preferably, the method further comprises a step of administering to a mammal in need thereof from is 0.1 to 50 mg per kg body weight of succinic acid or a pharmaceutically acceptable salt thereof orally or parenterally.

Abstract: This invention relates to compositions for disinfecting an inanimate surface comprising an effective disinfecting amount of a disinfectant and water, which water comprises from about 99.760 to about 99.999% of light isotopologue 1H2 160 and up to 100% of residual isotopologues 1H2170, 1H2180, 1H2H160, 1H2H170, 1H2H180, 2H2160, 2H2170, and 2H2180. The disinfectant is selected from the group consisting of aldehydes, alcohols, phenol compounds, quaternary ammonium compounds, chlorhexidine, halogen compounds, peroxides and hydroperoxides. Further, the invention relates to method of disinfecting an inanimate surface, which comprises a step of contacting said surface with the composition of the present invention.

Abstract: The invention relates to method for stimulating hair growth and regeneration in a mammal in need thereof, which comprises a step of applying to the skin of said mammal an effective amount of water comprising from about 99.760 to about 99.999% of light isotopologue 1H2160 and up to 100% of residual isotopologues 1H2170, 1H2180, 1H2H160 1H2H170, 1H2H180, 2H2160, 2H2170, and 2H2180. Preferably, the mammal is a human.

Abstract: The present invention relates to production of alcoholic beverage enriched with 1H216O in comparison with typical alcoholic beverage. This is provided by addition to alcoholic beverage highly pure light water comprising H216O from about 99.76% to about 99.99% by weight of water. The addition of highly pure light water to alcoholic beverage composition leads to lowering of the ethanol toxicity.

Abstract: The present invention relates to production of cosmetic composition enriched with 1H216O in comparison with typical cosmetic composition. This is provided by addition to cosmetic composition a highly pure light water comprising 1H216O from about 99.76% to about 99.999% by weight of water, while the content of 1H216O in typical water is no more than 99.575% by weight of water. According to the present invention cosmetic composition enriched with 1H216O in an amount no less than 99.76% by weight of water, includes cosmetic remedy, hygienic remedy, perfumed remedy, cosmetic makeup, water for washing, water for bath.

Abstract: The present invention relates to production of non-alcoholic beverage enriched with 1H216O in comparison with typical non-alcoholic beverage composition. This is provided by addition to alcoholic beverage highly pure light water comprising 1H216O from about 99.76% to about 99.99% by weight of water, while the content of 1H216O in typical water is no more than 99.575 by weight of water. According to the present invention non-alcoholic beverage enriched with 1H216O in an amount no less than 99.76% by weight of water, includes drinking water, table drinking water, mineralized water, mineral water, mineral table water, treatment-prophylactic mineral water, mineral-medicinal water; blended beverage which is table beverage, beverage for special purposes, refreshing beverage, cool beverage, tonic, lemonade, non-alcoholic cocktail; and beverage which is juice, nectar, kissel, mors, tea, kvass, non-alcoholic beer.

Abstract: This invention relates to pharmaceutical water, which comprises from 99.760 to 99.999% of light isotopologue 1H2 16O and up to 100% of residual isotopologues 1H2 17O, 1H2 18O, 1H2H16O, 1H2H17O, 1H2H 18O, 2H2 16O, 2H2 17O, and 2H2 18O, for the production of finished product, intermediate reagent preparation, and analytical processes in pharmaceutical industry. Further, the invention relates to pharmaceutical compositions comprising a biologically active agent and said pharmaceutical water, wherein said agent is selected from the group consisting of drugs, physiologically active peptides, physiologically active proteins, and nucleic acids. Further, the invention relates to method of administering a biologically active agent to a mammal in need thereof, which method comprises a step of administering to said mammal said therapeutic composition.